In cell cultures, the EliSpot (enzyme-linked immunosorbent spot assay) measures the number of activated T lymphocytes that secrete cytokines against the respective antigen.
The EliSpot (Interferon γ test) is a reliable cellular test for determining an infection with Borrelia and various co-pathogens. This first generation of the enzymatic EliSpot in combination with the determination of CD3- and CD57-NK-cells provides important additional information about the infection.
This test has been further developed and the new EliSpot, the so-called “LymeSpot revised”, provides detailed information on the activity of the infection. This test can differentiate between active (specific effector cells) and latent (specific memory cells) infections. Due to the new EliSpot, it is now possible to better evaluate infection, inflammation and autoimmune processes.
While the EliSpot is exclusively based on γ interferon production, the new LymeSpot also determines the cytokine IL-2. According to the “traffic light principle”, the result of an active infection (mainly effector cells) is green in the test. This means that it is necessary for the therapist to treat the infection. If the relationship between γ interferon and interleukin-2 changes in the opposite direction, a latent disease can be assumed, which is shown in the laboratory test as a red marking of the cells (mainly memory cells). In this case, mandatory anti-infective treatment would no longer be indicated.
2 x 8.5 ml CPDA tubes (do not centrifuge, store at room temperature, do not cool)
Analytical test duration:
(Note: Taking into account the pre- and post-analytical work processes, the findings report is usually prepared in approx. 1 week).
Accounting according to GOÄ:
- 3 x digit 3694 (3 different antigen approaches) Factor 1.15
- 1 x digit 4003 (lymphocyte isolation) factor 1.15
- 4 x digit 3694 (3 different antigen approaches) Factor 1.0
- 1 x digit 3696 Factor 1.0
- 1 x digit 4003 (lymphocyte isolation) factor 1,0